Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,798 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gel Clear all
Completed Not applicable Interventional

Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis

NCT03337243
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Joint Disease, Arthritis, Osteo Arthritis Knee, Musculoskeletal Disease
Interventions
HAM and HUMCWJ Injections
Procedure
Lead sponsor
Sport and Spine Rehab Clinical Research Foundation
Other
Eligibility
50 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 26, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional Results available

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

NCT01446250
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Beverly Hills, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 26, 2026, 3:57 AM EDT
Completed No phase listed Observational

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125
View directory record Official record
Conditions
Surgery
Interventions
TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen
Diagnostic Test
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 26, 2026, 3:57 AM EDT
Recruiting Not applicable Interventional

Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury

NCT06848140
View directory record Official record
Conditions
Traumatic Brain Injury, Word Finding Difficulty, Cognitive Symptom, Cognitive Change, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 26, 2026, 3:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

pH1N1 Blinded Challenge Study

NCT07110532
View directory record Official record
Conditions
Influenza
Interventions
A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 3:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Omega-3 Fatty Acids and Subconcussive Head Impacts

NCT06736925
View directory record Official record
Conditions
Subconcussive Head Impact, Omega-3 Fatty Acids
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Organic soybean oil, Soccer Heading Model
Dietary Supplement · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Treating Word Finding Difficulties in Traumatic Brain Injury With HD-tDCS

NCT06840808
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Change, Word Finding Difficulty, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity

NCT02476032
View directory record Official record
Conditions
Tooth Sensitivity
Interventions
Prof applied oxalate, Self applied oxalate, Prof applied placebo
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 26, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

NCT00171626
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac Topical Sodium Gel 1%
Drug
Lead sponsor
Novartis
Industry
Eligibility
35 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Corticotropin 80Unit/Ml Repository Injection
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 4 Interventional

Comparison of 2 Application Techniques for LET Gel Used Prior to Simple Laceration Repair

NCT04536493
View directory record Official record
Conditions
LET, Laceration of Skin
Interventions
LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application), LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
7 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 26, 2026, 3:57 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

FIH Lead-in Study of YASO GEL Followed by a Phase 1 Randomized, Double-blind Study to Assess Safety and Pharmacokinetics of YASO GEL

NCT07281404
View directory record Official record
Conditions
Early-phase Safety and PK Study of a Vaginal Gel
Interventions
YASO GEL, Placebo gel
Drug
Lead sponsor
Yaso Therapeutics Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 26, 2026, 3:57 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Testosterone and Neural Function in Men With Spinal Cord Injury

NCT06130449
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Natesto testosterone intranasal gel, Ayr Saline Nasal Gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Residual Antimicrobial Activity

NCT04495920
View directory record Official record
Conditions
Bacterial Overgrowth
Interventions
CGB-S-100
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 26, 2026, 3:57 AM EDT
Withdrawn Phase 4 Interventional

Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles

NCT02772120
View directory record Official record
Conditions
Infertility
Interventions
Vaginal progesterone gel (Crinone® 8%), Intramuscular Progesterone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

NCT01060670
View directory record Official record
Conditions
Neuropathic Diabetic Ulcer - Foot
Interventions
Integra® Dermal Regeneration Template, Conventional Wound Therapy
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
32
States / cities
Mobile, Alabama • Bakersfield, California • Castro Valley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

NCT02195583
View directory record Official record
Conditions
Oral Hygiene
Interventions
Sodium fluoride (1426 ppm), Sodium fluoride (1150 ppm), Sodium fluoride (250 ppm), Sodium fluoride (1426 ppm) + zinc base A, Sodium fluoride (1426 ppm) + zinc base B, Fluoride (0 ppm)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin

NCT02309294
View directory record Official record
Conditions
Cumulative Irritation
Interventions
Novel lubricant Miami w/ fragrance, Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

NCT00001906
View directory record Official record
Conditions
Cutaneous Leishmaniasis
Interventions
Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

NCT00168064
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
mechlorethamine-MCH (nitrogen mustard)
Drug
Lead sponsor
Yaupon Therapeutics
Industry
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Stanford, California • Chicago, Illinois • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 26, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00907387
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
RT001, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 26, 2026, 3:57 AM EDT